BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/25/2024 10:27:34 AM | Browse: 156 | Download: 662
 |
Received |
|
2024-06-21 13:04 |
|
Peer-Review Started |
|
2024-06-21 13:04 |
|
First Decision by Editorial Office Director |
|
2024-08-28 01:50 |
|
Return for Revision |
|
2024-08-28 01:50 |
|
Revised |
|
2024-09-10 12:11 |
|
Publication Fee Transferred |
|
2024-09-29 01:12 |
|
Second Decision by Editor |
|
2024-09-24 02:41 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-24 07:30 |
|
Articles in Press |
|
2024-09-24 07:30 |
|
Edit the Manuscript by Language Editor |
|
2024-10-07 11:19 |
|
Typeset the Manuscript |
|
2024-10-11 05:36 |
|
Publish the Manuscript Online |
|
2024-10-25 10:27 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hui Yang, Guang-Ping Qiu, Jie Liu and Tie-Quan Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tie-Quan Yang, BMed, Attending Doctor, Department of Interventional Therapy, Ningbo No. 2 Hospital, No. 41 Xibei Road, Ningbo 315000, Zhejiang Province, China. younghc5@163.com |
| Key Words |
Large hepatocellular carcinoma; Conventional transarterial chemoembolization; Drug-eluting beads transarterial chemoembolization; Programmed cell death 1 inhibitor; Lenvatinib |
| Core Tip |
A retrospective analysis encompassing 104 patients diagnosed with large hepatocellular carcinoma (≥ 5 cm), focused on comparing the efficacy and safety of two treatment modalities, which were the triple combination therapy drug-eluting beads transarterial chemoembolization (D-TACE), programmed cell death 1 inhibitor, and lenvatinib (D-TACE-P-L) and the triple therapy consisting of conventional TACE, programmed cell death protein 1 inhibitor, and lenvatinib. Progression-free survival, tumor response, and adverse events were compared between two groups, and the findings revealed that D-TACE-P-L demonstrated significantly superior median progression-free survival and objective response rate, while maintaining comparable toxicity profiles. Based on these outcomes, this study proposed that the D-TACE-P-L therapy served as a preferential treatment option for individuals suffering from large hepatocellular carcinoma. |
| Publish Date |
2024-10-25 10:27 |
| Citation |
Yang H, Qiu GP, Liu J, Yang TQ. Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(11): 4392-4401 |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i11/4392.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i11.4392 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
